Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Circ Genom Precis Med. 2022 Sep 22;15(5):e003675. doi: 10.1161/CIRCGEN.121.003675

Table 5.

Phenotypes in Carriers of Pathogenic/Likely Pathogenic Variants Associated with LMNA-related Cardiomyopathy

Carriers (N=6) Noncarriers (N=30) P value
Demographics
 Age, years 59.9 ± 10.6 59.9 ± 9.8 NA
 Female 3 (50%) 15 (50%)
 Genetic ancestry
  European 3 (50%) 15 (50%)
  African 3 (50%) 15 (50%)
Imaging
 Individuals with TTE or CMR 6 (100%) 25 (83%) 0.6
  Left ventricular ejection fraction, % 19 ± 8 41 ± 16 0.003
  Left ventricular end-diastolic diameter, cm 5.7 ± 1.0 5.4 ± 1.1 0.6
  Left atrial diameter, cm 4.8 ± 1.4 4.1 ± 0.9 0.4
 Nonischemic cardiomyopathy 5 (83%) 9 (30%) 0.02
Arrhythmias
 Symptomatic bradyarrhythmia 3 (50%) 2 (7%) 0.02
 Atrial fibrillation/flutter 4 (67%) 4 (13%) 0.01
 Nonsustained ventricular tachycardia 5 (83%) 4 (13%) 0.002
 Sustained ventricular tachycardia 4 (67%) 2 (7%) 0.003
Other findings
 Family history of heart failure 6 (100%) 4 (13%) 0.0001
 Syncope 1 (17%) 6 (20%) 1
 Permanent pacemaker 6 (100%) 7 (23%) 0.0009
 Implantable cardioverter-defibrillator 4 (67%) 5 (17%) 0.02
 Heart transplantation 5 (83%) 2 (7%) 0.0003
 Minimum eGFR, ml/min/1.73 m2 28 ± 23 47 ± 26 0.1
 Obstructive coronary artery disease 1 (17%) 16 (53%) 0.2

Continuous measures are described as mean ± standard deviation and are compared using the Wilcoxon rank-sum test. Categorical variables are described as N (%) and are compared using Fisher’s exact test. P values in bold indicate p <0.05. CMR, cardiac magnetic resonance imaging; eGFR, estimated glomerular filtration rate; NA, not applicable; TTE, echocardiogram.